Articles
257
All (257)
SCI-E, SSCI, AHCI (233)
SCI-E, SSCI, AHCI, ESCI (247)
ESCI (14)
Scopus (246)
TRDizin (42)
Other Publications (1)
27. Demonstration of therapy response to radioembolization with 90Y resin microspheres on 68Ga-PSMA PET/MRI in a patient with hepatocellular carcinoma
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
, vol.51, no.1, pp.316-317, 2023 (SCI-Expanded, Scopus)
36. Five years follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D
JOURNAL OF HEPATOLOGY
, vol.78, 2023 (SCI-Expanded)
38. Development of metabolic disorders in transplant recipients
JOURNAL OF HEPATOLOGY
, vol.78, 2023 (SCI-Expanded)
48. Factors associated with the development of extrahepatic malignancy in patients with nonalcoholic fatty liver disease: a single-center longitudinal study
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
, vol.34, no.11, pp.1172-1177, 2022 (SCI-Expanded)
49. FUNCTIONAL CURE WITH LONAFARNIB-BASED THERAPY IN CHRONIC HEPATITIS DELTA
HEPATOLOGY
, vol.76, 2022 (SCI-Expanded)
52. MEFIB AND MAST SCORES ASSESSMENT OF INCIDENT LIVER-RELATED OUTCOMES IN NONALCOHOLIC FATTY LIVER DISEASE: AN INDIVIDUAL PATIENT META-ANALYSIS
HEPATOLOGY
, vol.76, 2022 (SCI-Expanded, Scopus)
56. NATURAL DISEASE OUTCOMES IN PATIENT WITH NONALCOHOLIC FATTY LIVER DISEASE: A STUDY WITH PAIRED LIVER BIOPSIES
HEPATOLOGY
, vol.76, 2022 (SCI-Expanded)
61. Effectiveness of MRI methods in the assessment of hepatic steatosis in living liver donors
JOURNAL OF HEPATOLOGY
, vol.77, 2022 (SCI-Expanded)
63. Chronic hepatitis delta with normal ALT and hepatitis D viremia
JOURNAL OF HEPATOLOGY
, vol.77, 2022 (SCI-Expanded)
64. The course of COVID-19 infection in patients with chronic hepatitis B and Delta
JOURNAL OF HEPATOLOGY
, vol.77, 2022 (SCI-Expanded)
77. Covid-19 in Liver Transplant Recipients: A National Cohort
JOURNAL OF HEPATOLOGY
, vol.75, 2021 (SCI-Expanded)
80. Association between non-alcoholic fatty liver disease and extrahepatic malignancy
JOURNAL OF HEPATOLOGY
, vol.75, 2021 (SCI-Expanded)
81. Etiology of Cirrhosis in Turkey: A National Cohort Study
JOURNAL OF HEPATOLOGY
, vol.75, 2021 (SCI-Expanded)
92. MRI quantification techniques in fatty liver: the diagnostic performance of hepatic T1, T2, and stiffness measurements in relation to the proton density fat fraction
DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY
, vol.27, no.1, pp.7-14, 2021 (SCI-Expanded, Scopus, TRDizin)
137. Sequential development of acute autoimmune hepatitis may lead to a serious clinical picture in primary biliary cirrhosis
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
, vol.27, no.10, pp.1228-1229, 2015 (SCI-Expanded)
163. Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interactions
Journal of Pharmacology and Experimental Therapeutics
, vol.344, no.2, pp.388-396, 2013 (SCI-Expanded)
224. Repopulation of liver endothelial cells, but not hepatocytes, by allogeneic hematopoietic cell transplants.
BLOOD
, vol.98, no.11, 2001 (SCI-Expanded)
247. Cladribine therapy in chronic lymphoproliferative disorders: Single center experience
BRITISH JOURNAL OF HAEMATOLOGY
, vol.102, no.1, pp.244, 1998 (SCI-Expanded)
253. Polymerase chain reaction for the detection of HCV-RNA: cryoglobulinaemia as a cause for false negative results.
Italian journal of gastroenterology and hepatology
, vol.29, no.3, pp.273-4, 1997 (SCI-Expanded)
257. Protein C, protein S and antithrombin III levels in nephrotic syndrome.
BLOOD
, vol.88, no.10, pp.2982, 1996 (SCI-Expanded)
Papers Presented at Peer-Reviewed Scientific Conferences
141
1. WIDE VARIATIONS IN ANTIMICROBIAL GENE CARRIAGE IN PATIENTS WITH CIRRHOSIS AND HEALTHY CONTROLS FROM 7 COUNTRIES WITH 1020 PARTICIPANTS: IMPLICATIONS FOR RESISTANT INFECTIONS
Digestive Disease Week, California, United States Of America, 3 - 06 May 2025, vol.169, (Summary Text)
2. Gut metagenomic profiles predict 90-day hospitalizations despite controlling for diet, demographics & cirrhosis details in a multi-country cohort of patients with cirrhosis
European-Association-for-the-Study-of-the-Liver Congress, Amsterdam, Netherlands, 7 - 10 May 2025, vol.82, (Summary Text)
3. MAJOR VARIATIONS IN 90-DAY MORTALITY POST-HOSPITAL DISCHARGE AMONG INPATIENTS WITH CIRRHOSIS: A PROSPECTIVE COHORT STUDY FOR THE CLEARED CONSORTIUM
The Liver Meeting, California, United States Of America, 15 - 19 November 2024, (Summary Text)
6. Wide variations in proton pump inhibitor use in hospitalized patients with cirrhosis in a worldwide cohort shows little impact on clinically significant outcomes
European-Association-for-the-Study-of-the-Liver Congress (EASL), Milan, Italy, 5 - 08 June 2024, (Summary Text)
13. NON - INVASIVE FIBROSIS MARKERS FOR ASSESMENT OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS DELTA
Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 10 - 14 November 2023, vol.78, (Summary Text)
14. A STUDY OF ACUTE LIVER INJURY ASSOCIATED WITH ORNIDAZOLE: ANALYSIS OF 82 CASES IN TURKIYE
Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 10 - 14 November 2023, (Summary Text)
15. ALCOHOL-RELATED ETIOLOGY IS AN INDEPENDENT PREDICTOR OF INPATIENT MORTALITY IN PATIENTS WITH CIRRHOSIS IN A PROSPECTIVE GLOBAL CONSORTIUM
Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 10 - 14 November 2023, (Summary Text)
16. GLOBAL PREVALENCE OF INFECTIONS AND IMPACT OF REGIONAL VARIATIONS ON OUTCOMES: MULTI-NATIONAL CONSORTIUM OF CIRRHOSIS STUDY
Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 10 - 14 November 2023, (Summary Text)
17. PRIVATE INSURANCE ACCESS IS ASSOCIATED WITH HIGHER LIVER TRANSPLANT LISTING AND TRANSPLANT ACCESS AND LOWER MORTALITY COMPARED TO NATIONAL INSURANCES IN A LARGE MULTINATIONAL COHORT OF INPATIENTS WITH CIRRHOSIS
Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 10 - 14 November 2023, (Summary Text)
18. REGIONAL DIFFERENCES IN ACUTE KIDNEY INJURY PREVALENCE, CLINICAL CHARACTERISTICS AND PATIENT OUTCOMES IN A MULTI-NATIONAL CONSORTIUM OF INPATIENTS WITH CIRRHOSIS
Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 10 - 14 November 2023, (Summary Text)
52. MAGNETIC RESONANCE ELASTOGRAPHY AND TRANSIENT ELASTOGRAPGHY TO ASSESS HEPATIC STETAOSIS AND LIVER FIBROSIS IN THE LIVER TRANSPLANT SETTING
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 November 2020, vol.72, (Summary Text)
57. SIMILAR RISK OF HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT DURING LONG-TERM ENTECAVIR (ETV) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) THERAPY IN CAUCASIAN CHRONIC HEPATITIS B (CHB) PATIENTS
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70, (Summary Text)
58. ASSOCIATION BETWEEN NON-ALCOHOLIC FATTY LIVER DISEASE AND SUBCLINICAL ATHEROSCLEROSIS AND MYOCARDIAL DYSFUNCTION USING MULTIMODALITY IMAGING
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70, (Summary Text)
59. TREATMENT DISCONTINUATION IN HBEAG-NEGATIVE CHRONIC HEPATIT B IS A VIABLE OPTION IN NON-CIRRHOTIC GENOTYPE D CHRONIC HEPATITIS B PATIENTS
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70, (Summary Text)
60. NATURAL HISTORY OF INACTIVE HBsAg CARRIERS: A 10-YEAR PROSPECTIVE FOLLOW-UP STUDY
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70, (Summary Text)
61. TÜRKİYE’DE HEPATİT C ELİMİNASYONU YOL HARİTASI ÖNERİLERİ VE ÇALIŞTAY RAPORU
XI.Ulusal Viral Hepatit Simpozyumu, Turkey, 14 - 16 June 2019, (Summary Text)
64. Plasma metabolomic changes modulate the impact of Middle Eastern versus Western Diet in an international cirrhosis cohort
International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Austria, 10 - 14 April 2019, vol.70, (Summary Text)
70. ALT Levels and Risk of Hepatocellular Carcinoma (HCC) in Caucasian Chronic Hepatitis B (CHB) Patients Under Long-Term Therapy with Entecavir (ETV) or Tenofovir Disoproxil Fumarate (TDF)
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Costa Rica, 9 - 13 November 2018, vol.68, (Summary Text)
72. Prediction and Need for Surveillance of Hepatocellular Carcinoma (HCC) Development after the First 5 Years of Entecavir (ETV) or Tenofovir Disoproxil Fumarate (TDF) Therapy in Caucasian Chronic Hepatitis B (CHB) Patients of the PAGE-B Cohort
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Costa Rica, 9 - 13 November 2018, vol.68, (Summary Text)
74. Real world data on safety and efficacy of Ledipasvir Sofosbuvir ± RBV, Ombitasvir / Paritaprevir / Ritonavir ± Dasabuvir ± RBV combination therapy for chronic hepatitis C. A Turkey experience.
APASL Single Topic Conference, İstanbul, Turkey, 27 - 29 September 2018, (Summary Text)
75. HEPATİT C ENFEKSİYONUNA BAĞLI DEKOMPANZE SİROZ HASTALARINDA VE KRONİK HEPATİT C ENFEKSİYONU NEDENİYLE KARACİĞER NAKLİ OLANLARDA LEDİPASVİR/SOFOSBUVİR TEDAVİSİNİN ETKİLİLİĞİ: TÜRKİYE ERKEN ERİŞİM PROGRAMI SONUÇLARI
34. ULUSAL GASTROENTEROLOJİ HAFTASI, Turkey, 1 - 06 December 2017
78. EFFICIACY OF LEDİPASVİR AND SOFOSBUVİR WİTH/WİTHOUT TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH ADVANCED LIVER DISEASE RESULT OF A MULTICENTER TURKISH EARLY ACCES PROGRAM
VIRAL HEPATITIS (ENDORSED BY AASLD), 3 - 04 March 2017
79. Efficacy of ledipasvir and sofosbuvir with/without ribavirin for treatment of chronic hepatitis C patients with advanced liver disease results of a multicenter turkish early access program
Viral Hepatitis, 3 - 04 March 2017, (Summary Text)
80. Efficacy of ledipasvir and sofosbuvir with/without ribavirin for treatmentof hepatitis C patients Results of a multicenter Turkish Early Access Program
Viral Hepatitis, 3 - 04 March 2017, (Summary Text)
81. High incidence of significant liver fibrosis among HBeAg-positive patients with low levels of ALT
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 11 - 15 November 2016, vol.64, (Summary Text)
82. Chronic hepatitis D is a greater risk factor for hepatocellular carcinoma development than chronic hepatitis B
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 11 - 15 November 2016, vol.64, (Summary Text)
83. The Prenylation Inhibitor Lonafarnib Can Induce Post-Treatment Alt Flares With Viral Clearance In Patients With Chronic Delta Hepatitis
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 11 - 15 November 2016, vol.64, (Summary Text)
84. Exploring Optimal Dosing Of Lonafarnib With Ritonavir For The Treatment Of Chronic Delta Hepatitis-Interim Results From The Lowr Hdv-2 Study
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 11 - 15 November 2016, vol.64, (Summary Text)
85. The Role Of Genetic Variability Of PNPLA3 (rs738409) On Predispotion To Non-Alcoholic Fatty Liver Disease In Lean Patients
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 11 - 15 November 2016, vol.64, (Summary Text)
86. Hepatocellular carcinoma (HCC) is the only factor affecting the excellent survival of Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 11 - 15 November 2016, vol.64, (Summary Text)
87. The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 11 - 15 November 2016, vol.64, (Summary Text)
88. Hepatoselüler Kanserde Tedavi Yaklaşımı
Hepatoloji Okulu 2016, Turkey, 13 - 15 May 2016
89. Hepatitis delta virus kinetics under the prenylation inhibitor lonafarnib suggest HDV metiadted suppression of HBV replication
51th Annual Meeting of the European Association for the Study of the Liver (EASL), 13 - 17 April 2016
90. Hepatitis B (HBV) Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Lenalidomide Containing Regimens: A Single Center Experience
57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 5 - 08 December 2015, vol.126, (Summary Text)
91. Prolongation of interferon therapy increases maintained virological response rates and improves the natural course of chronic delta hepatitis
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Costa Rica, 13 - 17 November 2015, vol.62, (Summary Text)
92. Hepatitis C Seropositivity is not as high as Western Countries in the Population Born Between 1945-1965 According to Turkey Nationwide Hepatitis Prevalence Study (TURKHEP 2010)
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Costa Rica, 13 - 17 November 2015, vol.62, (Summary Text)
93. Decreasing risk of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Costa Rica, 13 - 17 November 2015, vol.62, (Summary Text)
94. "Normal" Serum ALT/AST Level in Turkish Population
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Costa Rica, 13 - 17 November 2015, vol.62, (Summary Text)
97. Vena Caval Replacement With Cadaveric Caval Graft for Living Donor Liver Transplantation in Budd-Chiari Syndrome Associated With Hydatid Cyst Surgery: A Case Report
21st Annual International Congress of the International-Liver-Transplant-Society (ILTS), Illinois, United States Of America, 8 - 11 July 2015, vol.99, pp.247-248, (Summary Text)
98. Multiple Genetic Mutations Increasing Thrombotic Risk Predisposing Both Donor and Recipient Thrombotic Complications After Living Donor Liver Transplantation: A Case Report
21st Annual International Congress of the International-Liver-Transplant-Society (ILTS), Illinois, United States Of America, 8 - 11 July 2015, vol.99, pp.278, (Summary Text)
101. Prognostic factors for prediction of survival of hepatocellular cancer patients after selective internal radiation therapy
Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), Missouri, United States Of America, 7 - 11 June 2014, vol.55, (Summary Text)
102. Hepatoselüler kanserli hastalarda selektif internal radyasyon tedavisi sonrası sağkalımı öngörmede prognostik faktörler
26.Ulusal Nükleer Tıp Kongresi, Turkey, 16 - 20 April 2014, pp.17, (Summary Text)
103. Prenylation inhibition with lonafarnib decreases hepatitis D levels in humans
65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 7 - 11 November 2014, vol.60, (Summary Text)
104. Timing of hepatocellular carcinoma (HCC) development and predictability of a modified PAGE-B risk score in caucasian chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir (TDF)
65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 7 - 11 November 2014, vol.60, (Summary Text)
105. The long-term efficacy of combination of nucleos(t)ide analogue treatment and low dose hepatitis b immunoglobulin on posttransplant HBV recurrence
65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 7 - 11 November 2014, vol.60, (Summary Text)
106. Early on-treatment HDV RNA kinetics are not predicitve for long-term response to a PEG-IFNa therapy of hepatitis delta
65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 7 - 11 November 2014, vol.60, (Summary Text)
107. Four years of tenofovir monotherapy for NUC naive field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013, vol.58, (Summary Text)
108. Risk and risk factors of hepatocellular carcinoma (HCC) in Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis treated with entecavir (ETV) or tenofovir (TDF)
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013, vol.58, (Summary Text)
109. Effectiveness and safety of entecavir and tenofovir in chronic hepatitis b patients: A multicenter Turkish study in clinical practice
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013, vol.58, (Summary Text)
110. Inactive hepatitis B carriers are prone to HBsAg loss rather than reactivation: a 5-year prospective follow-up study
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013, vol.58, (Summary Text)
111. INTERLEUKIN-28 (IL-28) GENE POLYMORPHISM (RS12979860 C/T) IS ASSOCIATED WITH PROGRESSION TO CHRONIC DELTA HEPATITIS INFECTION
62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Costa Rica, 4 - 08 November 2011, vol.54, (Summary Text)
112. IDENTIFICATION OF RISK FACTORS FOR FIBROSIS PROGRESSION IN NON-ALCOHOLIC FATTY LIVER DISEASE
61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 29 October - 02 November 2010, vol.52, (Summary Text)
114. RENAL TUBULER ACIDOSIS IN LIVER TRANSPLANT RECIPIENTS: THE EFFECT OF CALCINEURIN INHIBITORS.
15th Annual Congress of the International-Liver-Transplantation-Society, New York, United States Of America, 8 - 11 July 2009, vol.15, (Summary Text)
120. HBEAG-POSITIVE DELTA HEPATITIS: VIROLOGICAL; BIOCHEMICAL AND CLINICAL FEATURES IN A LARGE EUROPEAN MULTICENTER DATA BASE
59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, San-Francisco, Costa Rica, 31 October - 04 November 2008, vol.48, (Summary Text)
121. Complete genome sequences and phylogenetic analysis of hepatitis D viruses (HDV) isolated from turkish patients with chronic HDV infection
58th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 2 - 06 November 2007, vol.46, (Summary Text)
123. Insulin-sensitizer agents in the treatment of individuals with non-alcoholic steatohepatitis: A preliminary report
57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 27 - 31 October 2006, vol.44, (Summary Text)
124. Potential role of cytokine gene polymorphisms in outcome of chronic delta hepatitis
57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 27 - 31 October 2006, vol.44, (Summary Text)
125. Treatment of chronic hepatitis D (CHD) with interferon vs. interferon plus lamivudine vs. lamivudine: Short-and long-term results
56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, San-Francisco, Costa Rica, 11 - 15 November 2005, vol.42, (Summary Text)
126. The fate of recipient-derived repopulated hepatocytes in sex-mismatched liver allograft: A longitudinal study
56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, San-Francisco, Costa Rica, 11 - 15 November 2005, (Summary Text)
127. Potential role of cytokine gene polymorphisms in hepatitis B infection outcome
40th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Paris, France, 13 - 17 April 2005, vol.42, pp.230, (Summary Text)
131. PPAR-alpha L162V polymorphism in nonalcoholic steatohepatitis.
55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 29 October - 02 November 2004, vol.40, (Summary Text)
134. Recipient-derived hepatocytes in sex-mismatched living-related partial liver transplants.
54th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease, BOSTON, MASSACHUSETTS, 24 - 28 October 2003, (Summary Text)
135. The effect of hepatitis B virus status of the donor on the hepatitis B virus serology of the recipient after allogeneic hematopoietic cell transplantation
38th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, İstanbul, Turkey, 29 March - 01 April 2003, vol.38, pp.146, (Summary Text)
136. Lamivudine prophylaxis for prevention of chemotherapy induced hepatitis B virus reactivation in hepatitis B virus carriers with hematological malignancies
38th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, İstanbul, Turkey, 29 March - 01 April 2003, vol.38, pp.146-147, (Summary Text)
137. The effect of mycophenolate mofetil in steroid refractory or dependent chronic graft-versus-host disease
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Turkey, 23 - 26 March 2003, vol.31, (Summary Text)
138. The effect of hepatitis B virus status of donor on the hepatitis B virus serology of recipient after allogeneic hematopoietic cell transplantation
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Turkey, 23 - 26 March 2003, vol.31, (Summary Text)
140. The efficciency of ursodeoxycholic acid in treatment of limited chronic graft versus host disease of the liver.
44th Annual Meeting of the American-Society-of-Hematology, PHILADELPHIA, PENNSYLVANIA, 6 - 10 December 2002, vol.100, (Summary Text)
141. The long-term ursodeoxycholic acid treatment of chronic graft-versus-host disease of the liver.
53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD), BOSTON, MASSACHUSETTS, 1 - 05 November 2002, vol.36, (Summary Text)
Books
1
1. Türkiye Viral Hepatit Önleme ve Kontrol Programı” “Sağlık Bakanlığı Yayın No, Ankara
Sağlık Bakanlığı yayını Ankara, Ankara, 2018
Metrics
Publication
403
Open Access
37
UN Sustainable Development Goals
